Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection.

In conclusion, we successfully engineered a highly active and highly specific TALEN to disrupt CCR5, paving the way for its clinical application in hematopoietic stem cell grafts. This article is protected by copyright. All rights reserved.
PMID: 33103367 [PubMed - as supplied by publisher]

Source: Biotechnology Journal - October 25, 2020 Category: Biotechnology Authors: Romito M, Juillerat A, Kok YL, Hildenbeutel M, Rhiel M, Andrieux G, Geiger J, Rudolph C, Mussolino C, Duclert A, Metzner KJ, Duchateau P, Cathomen T, Cornu TI Tags: Biotechnol J Source Type: research